Jump to main content
Jump to site search

Issue 32, 2015
Previous Article Next Article

Investigation of antiglycation activity of isoprenaline

Author affiliations

Abstract

Advanced glycation end products (AGEs) are implicated in pathogenesis of diabetes and its complications. In this study, we report the ability of isoprenaline to inhibit the AGE modification of protein by fluorescence spectroscopy and western blotting. Isoprenaline was more effective in inhibiting AGE modification than aminoguanidine, a well known glycation inhibitor. Further, we show that isoprenaline inhibits at Amadori product formation during glycation reaction by various techniques such as MALDI-TOF-MS, LC-MS/MS, and fructosamine assay. Mass spectrometric analysis of the glycation reaction mixture incubated with isoprenaline suggested that it forms adducts with glucose and thus inhibits glycation. The finding of the additional property of isoprenaline of inhibiting glycation suggests that it is a potential candidate for drug repositioning for the treatment of diabetes and its complications, as it is an FDA approved drug.

Graphical abstract: Investigation of antiglycation activity of isoprenaline

Back to tab navigation

Supplementary files

Article information


Submitted
28 Jan 2015
Accepted
02 Mar 2015
First published
02 Mar 2015

RSC Adv., 2015,5, 25051-25058
Article type
Paper
Author version available

Investigation of antiglycation activity of isoprenaline

Y. M. Kolekar, G. Vannuruswamy, S. B. Bansode, S. B, H. V. Thulasiram and M. J. Kulkarni, RSC Adv., 2015, 5, 25051
DOI: 10.1039/C5RA01723H

Social activity

Search articles by author

Spotlight

Advertisements